CanSino Biologics Inc. (CASBF)
OTCMKTS
· Delayed Price · Currency is USD
3.200
-1.400 (-30.43%)
At close: Apr 9, 2025
CanSino Biologics Employees
CanSino Biologics had 1,105 employees as of December 31, 2024. The number of employees decreased by 389 or -26.04% compared to the previous year.
Employees
1,105
Change (1Y)
-389
Growth (1Y)
-26.04%
Revenue / Employee
$108,402
Profits / Employee
-$27,478
Market Cap
1.54B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,105 | -389 | -26.04% |
Dec 31, 2023 | 1,494 | -797 | -34.79% |
Dec 31, 2022 | 2,291 | 345 | 17.73% |
Dec 31, 2021 | 1,946 | 1,602 | 465.70% |
Dec 31, 2018 | 344 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Elite Pharmaceuticals | 64 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
American Oncology Network | 1,914 |
Northwest Biotherapeutics | 25 |
CytoDyn | 9 |
Silence Therapeutics | 116 |
CanSino Biologics News
- 2 months ago - CanSino Biologics CEO on earnings, business outlook, and international partnerships - CNBC
- 2 years ago - Riding Covid Vaccine Highs, CanSino Plans Swiss Listing - Seeking Alpha
- 2 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 3 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 3 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 3 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 3 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 3 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire